Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression

被引：18

作者：

Kuenzel, HE ^{[1
]}

Murck, H ^{[1
]}

Held, K ^{[1
]}

Ziegenbein, M ^{[1
]}

Steiger, A ^{[1
]}

机构：

[1] Max Planck Inst Psychiat, D-80804 Munich, Germany

来源：

PHARMACOPSYCHIATRY | 2004年 / 37卷 / 05期

关键词：

D O I：

10.1055/s-2004-827242

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Background: Reboxetine is a novel selective noradrenaline reuptake inhibitor. The antidepressive properties of the substance are established. Methods: The influence of reboxetine on the sleep-EEG of eight patients with depression HAMD (mean +/- SD) 19.7 +/- 1.5 (5 women, 3 men; age range 31 to 75 years) was investigated. Sleep EEG was examined twice. The first examination was performed before starting active medication. The second examination was subsequently performed when patients received 8 to 10 mg reboxetine per day. Results: Conventional sleep-EEG analysis showed a significant increase in intermittent wakefulness and sleep stage 2 and a decrease in sleep efficiency and REM time. Under reboxetine no significant changes were observed in sleep-EEG spectral analysis. Conclusion: Our results indicate, that reboxetine induces sleep-EEG changes similar to those after selective serotonin reuptake inhibitors (SSRI's) by increasing intermittent wakefulness and decreasing REM time.

引用

页码：193 / 195

页数：3

共 20 条

[1] PARADOXICAL SHORTENING OF REM LATENCY ON 1ST RECORDING NIGHT IN MAJOR DEPRESSIVE DISORDER - CLINICAL AND POLYSOMNOGRAPHIC CORRELATES [J].